Abstract
Hepatic diseases are turning into one of the few diseases that cannot be effectively cured due to some reasons although various receptors existed in the liver. Currently, several passive targeting delivery systems have been used in the drug/gene delivery for the treatment of hepatic diseases. For example, Zinostatin stimalamer (trade name of Smancs®), a drug-polymer conjugate, was launched in Japan in 1994, which treats hepatocellular carcinoma. More improtantly, different measures would be taken in accord to the specified cell that was lesioned or dysfunctioned via interaction between homing ligands and target receptors so as to improve accumulation of drugs in the target cell and to reduce nonspecific toxicity towards other cells or organs. Therefore, it is urgent to design novel delivery systems that physically or chemically grafted homing devices in order to improve the targeting properties of drugs in specific cell sites. From that perspective, the present article highlights recent development of active hepatic targeting drug/gene delivery systems for the treatment of hepatic diseases that were mediated by some kinds of receptors including asialoglycoprotein receptors (ASGP-R), glycyrrhetinic acid receptor (GA-R), glycyrrhizin receptor (GL-R), hyaluronan receptor (HA-R) and so on.
Keywords: Active hepatic targeting, drug carriers, drug delivery, homing ligands.
Current Drug Targets
Title:Recent Advances in Active Hepatic Targeting Drug Delivery System
Volume: 15 Issue: 6
Author(s): Yang Wang, Hongliang Du and Guangxi Zhai
Affiliation:
Keywords: Active hepatic targeting, drug carriers, drug delivery, homing ligands.
Abstract: Hepatic diseases are turning into one of the few diseases that cannot be effectively cured due to some reasons although various receptors existed in the liver. Currently, several passive targeting delivery systems have been used in the drug/gene delivery for the treatment of hepatic diseases. For example, Zinostatin stimalamer (trade name of Smancs®), a drug-polymer conjugate, was launched in Japan in 1994, which treats hepatocellular carcinoma. More improtantly, different measures would be taken in accord to the specified cell that was lesioned or dysfunctioned via interaction between homing ligands and target receptors so as to improve accumulation of drugs in the target cell and to reduce nonspecific toxicity towards other cells or organs. Therefore, it is urgent to design novel delivery systems that physically or chemically grafted homing devices in order to improve the targeting properties of drugs in specific cell sites. From that perspective, the present article highlights recent development of active hepatic targeting drug/gene delivery systems for the treatment of hepatic diseases that were mediated by some kinds of receptors including asialoglycoprotein receptors (ASGP-R), glycyrrhetinic acid receptor (GA-R), glycyrrhizin receptor (GL-R), hyaluronan receptor (HA-R) and so on.
Export Options
About this article
Cite this article as:
Wang Yang, Du Hongliang and Zhai Guangxi, Recent Advances in Active Hepatic Targeting Drug Delivery System, Current Drug Targets 2014; 15 (6) . https://dx.doi.org/10.2174/1389450115666140309232100
DOI https://dx.doi.org/10.2174/1389450115666140309232100 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Effects of Medications Used for the Management of Dyslipidemia on Postprandial Lipemia
Current Medicinal Chemistry Mouse Models of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Current Pharmaceutical Design The Role of Capecitabine in the Management of Tumors of the Digestive System
Reviews on Recent Clinical Trials Pyridines and Imidazopyridines with Medicinal Significance
Current Topics in Medicinal Chemistry Drug Metabolism in Chronic Renal Failure
Current Drug Metabolism Comparative Proteomics of Liver of the Diabetic Obese db/db and Non-Obese or Diabetic Mice
Current Proteomics A Review of the Immunosuppressive Activity of Cyclosporine Metabolites:New Insights into an Old Issue
Current Clinical Pharmacology Pharmacological Activity of Cardiovascular Agents from Herbal Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry Hormonal Effects on Drug Metabolism Through the CYP System: Perspectives on Their Potential Significance in the Era of Pharmacogenomics
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Histone Deacetylase Inhibitors Target Diabetes via Chromatin Remodeling or as Chemical Chaperones?
Current Diabetes Reviews Free Fatty Acids-Sensing G Protein-Coupled Receptors in Drug Targeting and Therapeutics
Current Medicinal Chemistry A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics?
Current Drug Metabolism Medicinal Chemistry and Pharmacology of A2B Adenosine Receptors
Current Topics in Medicinal Chemistry MicroRNAs in Organogenesis and Disease
Current Molecular Medicine Glycolipids as Immune Modulatory Tools
Mini-Reviews in Medicinal Chemistry Induction of Propranolol Metabolism by Ginkgo biloba Extract EGb 761 in Rats
Current Drug Metabolism The Role of Gut Microbiota in Drug Response
Current Pharmaceutical Design Prevention of Intracerebral Haemorrhage
Current Drug Targets Nutritional Assessment in the Critically Ill Child
Current Pediatric Reviews Comparison of High-Sensitive CRP, RDW, PLR and NLR between Patients with Chronic Obstructive Pulmonary Disease and Chronic Heart Failure
Current Respiratory Medicine Reviews